Pharmacological profile of the mechanisms involved in the external carotid vascular effects of the antimigraine agent isometheptene in anaesthetised dogs.
The present study set out to investigate the external carotid vascular effects of isometheptene in vagosympathectomised dogs, anaesthetised with pentobarbital. One-minute intracarotid (intra-arterial; i.a.) infusions of isometheptene (10, 30, 100 and 300 microg/min) produced dose-dependent decreases in external carotid blood flow, without affecting blood pressure or heart rate. The vasoconstrictor responses to 100 microg/min and 300 microg/min of isometheptene were clearly attenuated in animals pretreated with reserpine (5,000 microg/kg). Moreover, after prazosin (an alpha1-adrenoceptor antagonist; 100 microg/kg), the responses to isometheptene remained unaltered in untreated as well as reserpine-pretreated dogs. In contrast, the responses to isometheptene were attenuated by rauwolscine (an alpha2-adrenoceptor antagonist; 300 microg/kg) in untreated animals, and were practically abolished in reserpine-pretreated dogs. Further investigation into the specific alpha2-adrenoceptor subtypes, using selective antagonists, showed that BRL44408 (alpha2A) and MK912 (alpha2C) markedly attenuated this response, while imiloxan (alpha2B) was ineffective. The involvement of 5-HT1B and 5-HT1D receptors seems highly unlikely since antagonists at 5-HT1B (SB224289) and 5-HT1D (BRL15572) receptors (both at 300 microg/kg) were ineffective. On this basis, it is concluded that isometheptene-induced canine external carotid vasoconstriction is mediated by both indirect (a tyramine-like action) and direct (acting at receptors) mechanisms, which mainly involve alphaA- and alpha2C-adrenoceptors, while the involvement of alpha1-adrenoceptors seems rather limited.
Willems
E W
EW
Department of Pharmacology, Erasmus University Medical Centre Rotterdam, The Netherlands.
Valdivia
L F
LF
Saxena
P R
PR
Villalón
C M
CM
D000758:Anesthesia; D000818:Animals; D002342:Carotid Artery, External / Q000187:drug effects* / Q000502:physiology; D004285:Dogs; D006439:Hemodynamics / Q000187:drug effects; D008744:Methylamines / Q000737:chemistry / Q000494:pharmacology*; D008881:Migraine Disorders / Q000188:drug therapy; D023421:Models, Animal; D015394:Molecular Structure; D011224:Prazosin / Q000494:pharmacology; D044302:Receptor, Serotonin, 5-HT1B; D044346:Receptor, Serotonin, 5-HT1D; D018340:Receptors, Adrenergic, alpha-1 / Q000378:metabolism; D018341:Receptors, Adrenergic, alpha-2 / Q000378:metabolism; D011985:Receptors, Serotonin / Q000187:drug effects; D012039:Regional Blood Flow / Q000187:drug effects / Q000502:physiology; D012110:Reserpine / Q000494:pharmacology; D013562:Sympathectomy; D013566:Sympathomimetics / Q000737:chemistry / Q000494:pharmacology*; D014628:Vagotomy; D014662:Vasoconstrictor Agents / Q000494:pharmacology*
D008744:Methylamines; D044302:Receptor, Serotonin, 5-HT1B; D044346:Receptor, Serotonin, 5-HT1D; D018340:Receptors, Adrenergic, alpha-1; D018341:Receptors, Adrenergic, alpha-2; D011985:Receptors, Serotonin; D013566:Sympathomimetics; D014662:Vasoconstrictor Agents; D012110:Reserpine; D011224:Prazosin; C008192:isometheptene